What is the official website of Novartis México ?

The official website of Novartis México is www.novartis.com/mx-es.

What is Novartis México's cybersecurity risk score?

Novartis México has an AI-generated cybersecurity risk score of 759 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Novartis México experienced?

According to Rankiteo, Novartis México currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Novartis México been affected by any supply chain cyber incidents ?

According to Rankiteo, Novartis México has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Novartis México have SOC 2 Type 1 certification ?

According to Rankiteo, Novartis México is not certified under SOC 2 Type 1.

Does Novartis México have SOC 2 Type 2 certification ?

According to Rankiteo, Novartis México does not hold a SOC 2 Type 2 certification.

Does Novartis México comply with GDPR ?

According to Rankiteo, Novartis México is not listed as GDPR compliant.

Does Novartis México have PCI DSS certification ?

According to Rankiteo, Novartis México does not currently maintain PCI DSS compliance.

Does Novartis México comply with HIPAA ?

According to Rankiteo, Novartis México is not compliant with HIPAA regulations.

Does Novartis México have ISO 27001 certification ?

According to Rankiteo,Novartis México is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Novartis México operate in ?

Novartis México operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Novartis México have ?

Novartis México employs approximately 607 people worldwide.

Does Novartis México own any subsidiaries ?

Novartis México presently has no subsidiaries across any sectors.

How many LinkedIn followers does Novartis México have ?

Novartis México's official LinkedIn profile has approximately 96,715 followers.

What is the NAICS classification code for Novartis México ?

Novartis México is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Novartis México have a Crunchbase profile ?

No, Novartis México does not have a profile on Crunchbase.

Does Novartis México have a LinkedIn profile ?

Yes, Novartis México maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/novartismexico.

How many cybersecurity incidents has Novartis México experienced ?

As of June 23, 2026, Rankiteo reports that Novartis México has experienced 2 cybersecurity incidents.

How many peer or competitor companies does Novartis México have ?

Novartis México has an estimated 5,695 peer or competitor companies worldwide.

What types of cybersecurity incidents has Novartis México faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach and Cyber Attack.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Novartis México

Boost Score +25 with badge (5 left)

759

/1000

Fair

784

/1000

Fair

Novartis México Vendor Cyber Rating & Cyber Score

novartis.com

Add Your Compliance Badge

Novartis Farmacéutica, S.A. de C.V. es individualmente “Responsable” de recabar sus datos personales, con domicilio en Av. Insurgentes Sur 2475, Tizapán San Ángel, Álvaro Obregón, 01090 Ciudad de México. Los datos personales que usted nos proporcione serán utilizados para cumplimentar la legislación respectiva. Para consultar nuestro Aviso de Privacidad Integral y los mecanismos para ejercer sus derechos, por favor visite www.novartis.com/mx-es Somos una compañía global con base en Suiza en la que buscamos descubrir nuevos caminos para prolongar y mejorar la vida de los pacientes en el mundo. Debes estar al tanto de los anuncios de trabajo falsos. En Novartis estamos consciente de las estafas recientes que hacen mal uso del nombre de

Novartis México A.I CyberSecurity Scoring

Scoring History

Novartis México

Novartis México CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Novartis

Breach

2/2026

NOV1774449180

Novartis México

Cyber Attack

100

06/2022

NOV21267722

Loading…

A.I.

Novartis México Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Novartis México

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis México in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Novartis México in 2026.

Incident Types Novartis México vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis México in 2026.

Incident History - Novartis México (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Novartis México Subsidiaries

Novartis México

Pharmaceutical Manufacturing

Website: www.novartis.com/mx-es

Company Size: 607

NovartisPharmaceutical Manufacturing

Novartis IndiaPharmaceutical Manufacturing

Novartis SciencePharmaceutical Manufacturing

Novartis Gene TherapiesBiotechnology Research

Novartis SlovakiaPharmaceutical Manufacturing

Novartis SingaporePharmaceutical Manufacturing

Novartis EspañaPharmaceutical Manufacturing

Novartis DanmarkPharmaceutical Manufacturing

Novartis SverigePharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis FinlandPharmaceutical Manufacturing

Novartis, Australia & New ZealandPharmaceutical Manufacturing

Novartis MagyarországPharmaceutical Manufacturing

Novartis SerbiaPharmaceutical Manufacturing

Novartis IsraelPharmaceutical Manufacturing

Novartis Hong KongPharmaceutical Manufacturing

Novartis MedicalPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis ItaliaPharmaceutical Manufacturing

Novartis RomâniaPharmaceutical Manufacturing

Novartis NederlandPharmaceutical Manufacturing

Novartis Nederland - NeurologieGeneesmiddelenproductie

Novartis Nederland - OncologieGeneesmiddelenproductie

Novartis Nederland - ReumatologieGeneesmiddelenproductie

Novartis Nederland - HematologieGeneesmiddelenproductie

Novartis Nederland - DermatologieGeneesmiddelenproductie

Novartis Nederland - Cardiovascular, Renal & Metabolism Geneesmiddelenproductie

Novartis NorgePharmaceutical Manufacturing

Novartis BrasilPharmaceutical Manufacturing

Novartis USPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis DeutschlandPharmaceutical Manufacturing

Novartis ColombiaPharmaceutical Manufacturing

Novartis CanadaPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis in SloveniaPharmaceutical Manufacturing

Novartis Gulf | نوفارتس الخليجPharmaceutical Manufacturing

Novartis ArgentinaPharmaceutical Manufacturing

Novartis Ireland Pharmaceutical Manufacturing

Novartis US MedicalPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis BeluxPharmaceutical Manufacturing

Novartis PortugalPharmaceutical Manufacturing

Loading…

Novartis México Similar Companies

Astellas Pharma

astellas.com

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

Novo Nordisk

novonordisk.com

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. Our unordinary mindset is at the heart of everything we do. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 77,000 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

Hikma Pharmaceuticals

cb hikma.com

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

Takeda

cb takeda.com

We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities. Read our community guidelines: https://takeda.info/communityguidelines

MANKIND PHARMA LTD

mankindpharma.com

Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 20,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. We take great pride in the success of our products ranging from Pharma, OTC and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel and many others. Our operations are in 34 overseas destinations across Asia, Africa, South-East Asia, Gulf countries and CIS countries. Our Vision - To be a global pharmaceutical company, most admired for its Affordability, Quality and Accessibility of products. Our Mission - To be able to provide cost-effective, innovation based superior quality pharmaceutical products across the globe, to improve the lives of the patients. Mankind strongly believes and follows its Core Values: 𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫 𝐂𝐞𝐧𝐭𝐫𝐢𝐜𝐢𝐭𝐲: Commitment to Customer - Internal and External 𝐐𝐮𝐚𝐥𝐢𝐭𝐲: It is in our DNA to maintain and deliver highest quality standards and products 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Intensely Research driven organization aiming at product innovation and technology improvements 𝐈𝐧𝐭𝐞𝐠𝐫𝐢𝐭𝐲: Always trustworthy, widely respected to be honest, and believed by everyone 𝐆𝐨 𝐁𝐞𝐲𝐨𝐧𝐝: Aim higher than capabilities 𝐏𝐞𝐨𝐩𝐥𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧: Together we are foreseeing future and diligently stimulating our people in attaining goals

MACLEODS PHARMACEUTICALS LTD.

macleodspharma.com

A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers. Our Vision To be a leading global pharmaceutical company by providing high quality, affordable and innovative therapeutic solutions for patients with diverse medical needs. Our Mission To contribute towards improving patients’ quality of life across the globe, by providing effective and accessible medicines.

Zydus Group

zyduslife.com

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries.

Novartis

cb novartis.com

Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki

MSD

msd.com

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on Facebook, Instagram, Twitter, and YouTube.

Loading…

NEWS

Novartis México CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

January 25, 2026 08:00 AM

Novartis Renews WHO Commitment to Treat Leprosy by 2030

Novartis renewed its commitment with the WHO to treat 1 million more leprosy patients by 2030, extending a long-running global health...

Read Article

August 13, 2025 07:00 AM

Dräger’s Atlan A350 Series Gains US DoD Security Certification

Dräger's Atlan A350 anesthesia workstation series earns US DoD cybersecurity certification, securing patient data in operating rooms.

Read Article

February 22, 2021 08:00 AM

Treatment Access: Priority in Mexico

The Access to Medicine Foundation reveals that Mexico is among the countries with more strategies for therapies access.

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-54236

SUMMARY

vLLM is an inference and serving engine for large language models (LLMs). Prior to 0.23.1rc0, the fix for CVE-2026-22778, which introduced a sanitize_message helper that strips object-repr memory addresses from error messages before they reach the client, is incomplete: several response paths echo str(exc) directly to clients without calling sanitize_message. The unsanitized sites include the Anthropic API router in vllm/entrypoints/anthropic/api_router.py (the POST /v1/messages and POST /v1/messages/count_tokens handlers), the Server-Sent Events streaming converter in vllm/entrypoints/anthropic/serving.py, and the realtime speech-to-text WebSocket in vllm/entrypoints/speech_to_text/realtime/connection.py. These paths catch the exception inside the route coroutine and construct the JSONResponse themselves, bypassing the sanitizing global FastAPI exception handler, and WebSocket frames do not traverse that handler chain at all. Using the same primitive as the parent issue, an unauthenticated attacker can send malformed image bytes through the Anthropic Messages API image content parts so that PIL.Image.open raises an UnidentifiedImageError whose message contains the BytesIO object repr, leaking the heap memory address verbatim in the error.message field of the response body. This vulnerability is fixed in 0.23.1rc0.

Published

Date2026-06-22

Updated

Date2026-06-22

RISK INFORMATION (Score: 5.3)

cvss3

Base Score: 5.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:N/A:N

Impact Score

1.4

Exploitability

3.9

REFERENCES

CVE-2026-54235

SUMMARY

vLLM is an inference and serving engine for large language models (LLMs). Prior to 0.23.1rc0, ll temperature validation gates use comparison operators (<, >), which silently evaluate to False for NaN and for positive Infinity in Python's IEEE 754 float semantics. Both values pass every guard and propagate to GPU sampling kernels, where they produce undefined behavior or CUDA errors that can crash the inference worker. This vulnerability is fixed in 0.23.1rc0.

Published

Date2026-06-22

Updated

Date2026-06-22

RISK INFORMATION (Score: )

cvss4

Base Score: 6.9

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-54233

SUMMARY

vLLM is an inference and serving engine for large language models (LLMs). Prior to 0.23.1rc0, vLLM's /v1/audio/transcriptions endpoint limits compressed upload size but not decoded PCM output. A 25MB OPUS file expands to ~14.9GB of float32 PCM at decode time. This vulnerability is fixed in 0.23.1rc0.

Published

Date2026-06-22

Updated

Date2026-06-22

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

2.8

REFERENCES

CVE-2026-54232

SUMMARY

vLLM is an inference and serving engine for large language models (LLMs). Prior to 0.22.1, the vLLM Dockerfile is vulnerable to a dependency confusion attack through the flashinfer-jit-cache package. The package is installed from a custom index (flashinfer.ai/whl/) using --extra-index-url, but the package name was not registered on PyPI, and UV_INDEX_STRATEGY="unsafe-best-match" is set globally. An attacker who registers flashinfer-jit-cache on PyPI with version 0.6.11.post2 can execute arbitrary code as root during the Docker build and backdoor every resulting container image, enabling exfiltration of all user prompts, API credentials, and model data from production vLLM deployments This vulnerability is fixed in 0.22.1.

Published

Date2026-06-22

Updated

Date2026-06-22

RISK INFORMATION (Score: 8.8)

cvss3

Base Score: 8.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

2.8

REFERENCES

https://github.com/vllm-project/vllm/security/advisories/GHSA-jrf6-vqxq-pjv2

CVE-2026-53923

SUMMARY

vLLM is an inference and serving engine for large language models (LLMs). From 0.5.5 until 0.23.1rc0, integer truncation of tensor dimensions in vLLM's GGUF dequantize kernels (csrc/quantization/gguf/gguf_kernel.cu) causes partial tensor processing. The output tensor is allocated at full size via torch::empty (uninitialized memory), but the dequantize CUDA kernel processes only a truncated number of elements. The unfilled portion of the output tensor retains whatever was previously in GPU memory. In multi-tenant inference deployments, this residual GPU memory may contain tensor data from other users' inference requests, constituting information disclosure. This vulnerability is fixed in 0.23.1rc0.

Published

Date2026-06-22

Updated

Date2026-06-22

RISK INFORMATION (Score: )

cvss4

Base Score: 5.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:L/VI:L/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…